Autentificare
NeuroPsy InfoHubÎnțelege · Sprijin · ProgresCere sprijin
← Toate temele

Scleroză multiplă

Scleroza multiplă și viața cu aceasta.

71 de articole
← Toate secțiunile

Studii și știri

PublicToțiPentru oricineSpecialiști
VârstăToate vârsteleCopiiTineriAdulțiVârstnici
StudiuScleroză multiplăÎncredere înaltă23.06.2026

Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial

A 12-month randomized controlled trial evaluated dulaglutide (a GLP-1 receptor agonist) as adjunctive therapy alongside natalizumab in 28 patients with relapsing-remitting MS, measuring neurofilament light chain levels, brain MRI changes, and functional outcomes. Treatment with dulaglutide significantly reduced weight, BMI, and body fat while improving glucose tolerance and potentially showing neuroprotective effects.

StudiuScleroză multiplăÎncredere bună22.06.2026

Multiple Sclerosis in Morocco: Epidemiological, Clinical, and Therapeutic Profile

A descriptive study of 170 MS patients across Morocco found female predominance, relapsing-remitting MS as the most common type, and common symptoms including fatigue, cognitive issues, and spasticity. Disease-modifying therapies (interferon beta-1a, azathioprine) were used alongside traditional/complementary medicine (cupping, Quranic recitation, apitherapy), with professional activity, treatment satisfaction, and stress significantly associated with relapse frequency.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Neuroimaging Advances for Monitoring Multiple Sclerosis Worsening: GMSI-Supported Innovations

This review examines recent neuroimaging technologies including MRI, PET, ocular imaging, and machine learning supported by MS research initiatives to better detect early MS pathology and monitor treatment response. The authors emphasize that while these biomarkers show promise for predicting and monitoring disease progression and may serve as clinical trial endpoints, longitudinal studies are needed to translate these measures into routine clinical practice.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Biological aging in multiple sclerosis: mechanisms and therapeutic implications

This review examines how biological aging accelerates disease progression in multiple sclerosis, particularly in progressive forms resistant to current treatments. Evidence from animal models and clinical biomarkers (telomere length, DNA methylation) suggests MS patients experience accelerated aging, opening potential avenues for senotherapy-based interventions targeting aging-related pathways.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Reduced resting beat-to-beat blood pressure variability in females with relapsing-remitting multiple sclerosis

This study examined cardiovascular autonomic dysfunction in women with relapsing-remitting MS by measuring beat-to-beat blood pressure variability and sympathetic baroreflex sensitivity compared to healthy controls. The research hypothesized that reduced sympathetic control in MS patients leads to impaired blood pressure regulation, using continuous electrocardiogram and blood pressure monitoring along with muscle sympathetic nerve activity recordings.

StudiuScleroză multiplăÎncredere bună22.06.2026

The dual role of autophagy in multiple sclerosis: Protective and harmful mechanisms

This review examines autophagy—a cellular degradation process—as a double-edged sword in multiple sclerosis, showing both protective effects (reducing oxidative stress and inflammation) and harmful effects (promoting demyelination when over-activated). The paper discusses how autophagy modulates immune cell activation and oligodendrocyte function, suggesting selective autophagy modulation could be a therapeutic strategy depending on disease context.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Magnetic resonance fingerprinting in multiple sclerosis: T1 and T2 relaxation time analysis in tissue characterization

This cross-sectional study used magnetic resonance fingerprinting (MRF) to measure T1 and T2 relaxation times in brain tissue of healthy controls, relapsing-remitting MS patients, and secondary progressive MS patients, finding progressive increases in relaxation times across disease stages. The findings suggest MRF may be useful for quantitative tissue characterization and differentiation between MS disease subtypes and disease progression.

StudiuScleroză multiplăÎncredere bună22.06.2026

Neuropsychological Rehabilitation in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review

This systematic review examines scientific evidence on neuropsychological interventions targeting cognitive impairment in people with relapsing-remitting MS, a common disabling neurological disease in young adults. Analysis of 15 articles meeting rigorous inclusion criteria found that most cognitive rehabilitation programs demonstrated effectiveness, though methodological standardization remains lacking in this field.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Horizontal gene transfer in pathogenic bacteria shapes progressive multiple sclerosis

Research identifies a specific strain of Tyzzerella nexilis enriched in secondary progressive MS that carries numerous mobile genetic elements and lacks defence mechanisms against them. In germ-free mice, colonisation with this strain increases susceptibility to experimental autoimmune encephalomyelitis through TLR5 stimulation by flagella and production of neuroactive reduced sulphur compounds, suggesting horizontal gene transfer may drive MS progression via gut microbiome alterations.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Executive Functions in Relapsing-Remitting Multiple Sclerosis: A Comparative Study of Working Memory and Cognitive Control

This study compared executive function performance in 24 individuals with relapsing-remitting multiple sclerosis and 24 matched healthy controls using standardized cognitive tests. Results showed selective impairment in divided attention and working memory updating in MS patients under high cognitive demand, while attentional shifting and inhibition remained intact.

StudiuScleroză multiplăÎncredere înaltă21.06.2026

Serum Biomarkers of Response to Ocrelizumab in Relapsing-Remitting Multiple Sclerosis

A multicenter prospective study measured serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels in 115 relapsing-remitting MS patients treated with ocrelizumab over one year to identify biomarkers predicting treatment response. Elevated baseline sNfL and sGFAP levels were associated with treatment failure due to ongoing inflammation, while most patients with progression without relapse showed low sNfL levels, suggesting these biomarkers may help predict which patients will achieve disease activity remission.

StudiuScleroză multiplăÎncredere bună21.06.2026

Serum pleiotrophin levels in patients with multiple sclerosis

This prospective study compared serum pleiotrophin (PTN) levels in 168 MS patients across three disease subtypes (RRMS, PPMS, SPMS) against 41 healthy controls, finding significantly lower PTN levels in MS patients overall and in RRMS and SPMS subgroups. The findings suggest pleiotrophin may play a role in MS pathogenesis and could be investigated as a potential biomarker for certain disease phenotypes.

StudiuScleroză multiplăÎncredere înaltă21.06.2026

Multiple Sclerosis: Pathophysiology, Clinical Presentation, and Disease Course Classification

Multiple sclerosis is a chronic autoimmune disorder of the central nervous system characterized by demyelination, inflammation, and progressive neuronal loss, presenting with diverse neurological symptoms including vision problems, sensory changes, weakness, and cognitive decline. The disease exhibits distinct clinical courses—relapsing-remitting (70-80% of cases), primary progressive (15-20%), and secondary progressive forms—with symptom onset typically in young adulthood and variable progression timelines.

StudiuScleroză multiplăÎncredere bună21.06.2026

A Ceramide Theory of Multiple Sclerosis

This theoretical framework proposes that MS pathogenesis involves TNFα-induced breakdown of ceramide-based membrane stabilizers (sphingomyelin and galactosylceramide), facilitating immune cell infiltration across the blood-brain barrier and myelin damage. The mechanism explains disease relapsing-remitting patterns and aligns with current B-cell targeted therapeutic approaches.